Trial Search Results

A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies

This study will examine the safety profile of SGN-35 alone and in combination with gemcitabine. The study will test increasing doses of SGN-35 given weekly to small groups of patients.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Seagen Inc.

Stanford Investigator(s):

Intervention(s):

  • Drug: SGN-35
  • Drug: gemcitabine

Phase:

Phase 1

Eligibility


Inclusion Criteria:

   - Histologically confirmed CD30-positive hematologic malignancy.

   - Patients with HL must have failed systemic chemotherapy.

   - Patients with other CD30-positive malignancies (including ALCL) must be beyond first
   remission or refractory to front line chemotherapy.

   - Patients must have measurable disease of at least 1.5 cm as documented by radiographic
   technique.

Exclusion Criteria:

   - Current diagnosis of primary cutaneous ALCL (systemic ALCL eligible).

   - History of allogeneic stem cell transplant.

   - Patients who have had previous treatment with any anti-CD30 antibody.

Ages Eligible for Study

12 Years - N/A

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Euodia Jonathan
6507256432
Not Recruiting